HIV/AIDS Drug Resistance: HIV-1 K65R mutation may emerge preferentially in absence of zidovudine and TAMs

AIDSWEEKLY Plus; Monday, July 31, 2006
Staff Medical Writers

According to recent research published in the journal HIV Medicine, "The K65R HIV-1 reverse transcriptase (RT) mutation is a multidrug resistance mutation which may be correlated with specific antiretroviral combinations and with the presence or absence of other RT resistance mutations.

"The aims of this study were: (1) to determine the prevalence of the K65R mutation in a cohort of antiretroviral-treated patients; (2) to study genotypic patterns and treatment characteristics in patients in whom the K65R mutation was present."

"We included in the study all antiretroviral-experienced patients followed up at the Bordeaux University Hospital in 2003 and 2004 for whom an HIV-1 genotypic resistance analysis was available.

"Information on RT resistance mutations was reported from a hospital database including therapeutic and biological parameters. The prevalence of K65R was investigated for all patients. Genotypic patterns and treatment characteristics were examined at the time of detection of the K65R mutation," researchers wrote.

"The prevalence of K65R was 1.9% (26 of 1404 patients). K65R was associated with nucleoside RT inhibitor-based regimens in 22 patients, and with tenofovir disoproxil fumarate, lamivudine, didanosine and abacavir in 23, 17, 17 and eight patients, respectively.

"The M184V and Q151M mutations were the most commonly coselected substitutions. Thymidine analogue mutations (TAMs) were rarely coselected with K65R and inversely associated with K65R," reported S. Boucher and colleagues at CHU de Bordeaux.

The authors concluded, "The K65R mutation may emerge preferentially in the absence of zidovudine and TAMs, suggesting the possibility of an antagonistic interaction between K65 and TAMs."

Boucher and colleagues published their study in HIV Medicine (HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med, 2006;7(5):294-298).

For additional information, contact B. Masquelier, Hopital Pellegrin, Dept. of Virology & Immunology Biology, Pl Amelie Raba Leon, F-33076 Bordeaux, France.

The publisher's contact information for the journal HIV Medicine is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Bordeaux, France, HIV/AIDS, Drug Resistance, K65R Mutation, Thymidine Analogue Mutation, Zidovudine.

This article was prepared by AIDS Weekly editors from staff and other reports.

2006-07-31
AW060714

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.